tetrabutylammonium triphenyldifluorosilicate: used to convert 6-chloropurine nucleosides to 6-fluoropurine derivatives [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9893474 |
| CHEMBL ID | 1077766 |
| MeSH ID | M0356896 |
| Synonym |
|---|
| tetrabutylammonium difluorotriphenylsilicate |
| tbat |
| 163931-61-1 |
| T1909 |
| CHEMBL1077766 |
| tetrabutylammonium difluorotriphenylsilicate(iv) |
| AKOS024462927 |
| DTXSID60432449 |
| CS-W004963 |
| mfcd00274218 |
| tetrabutylammonium triphenyldifluorosilicate (tbat) |
| tetrabutylammonium triphenyldifluorosilicate |
| DS-9421 |
| RQBKGJOQACIQDG-UHFFFAOYSA-N |
| difluoro(triphenyl)silanuide;tetrabutylazanium |
| BCP10117 |
| tetrabutylamoniumdifluorotriphenylsilicate |
| A882499 |
| tetrabutylammoniumdifluorotriphenylsilicate(iv) |
| difluorotriphenylsilanuide; tetrabutylazanium |
| EN300-7408594 |
| HY-W004963 |
| tetrabutylammonium triphenyldifluoro-sil |
| PD196407 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID470205 | Antimicrobial activity against Escherichia coli K-12 C600 assessed as ratio of maximum zone of inhibition to concentration required to reach half maximum zone of inhibition after 24 hrs | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17 | Development of a novel expression, ZI MAX/K ZI, for determination of the counter-anion effect on the antimicrobial activity of tetrabutylammonium salts. |
| AID470206 | Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 assessed as ratio of maximum zone of inhibition to concentration required to reach half maximum zone of inhibition after 24 hrs | 2009 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17 | Development of a novel expression, ZI MAX/K ZI, for determination of the counter-anion effect on the antimicrobial activity of tetrabutylammonium salts. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.78) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||